Fig. 6.

Reduced inflammation and expression of fibrotic markers after CL27c inhalation in a moderate protocol of bleomycin-induced lung fibrosis. a Protocol for Bleomycin-induced lung injury, elicited by intranasal instillation of 2 mg/kg Bleomycin (Bleo), and treatment regimen with aerosolized CL27c (2 mg/ml). b Quantification of macrophages, neutrophils, and lymphocytes content in BALF in control and CL27c-treated mice (from left to right macrophages n = 4, 5, 10, neutrophils n = 5, 5, 10, and lymphocytes n = 5, 5, 9 independent experiments, respectively). c Analysis of myeloperoxidase (MPO) expression in the lungs of control and CL27c-treated mice (from left to right n = 4, 5, 7 independent experiments, respectively). d Measurement of active levels of TGF-β with or without CL27c inhalation (from left to right n = 8, 5, 9 independent experiments, respectively). e Quantification of the expression of selected pro-fibrotic genes, including transforming growth factor-β (Tgfb1), connective tissue growth factor (Ctgf), collagen type-1 (Col1a1), and matrix metalloproteinase-2 (Mmp2) (from left to right, Tgfb1 n = 5, 10, 12, Ctgf n = 7, 17, 17, Colla1 n = 12, 10, 13, and Mmp2 n = 11, 10, 12 independent experiments, respectively). Results represent mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001 determined using one-way ANOVA followed by Bonferroni post-hoc test